<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="95576">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01658956</url>
  </required_header>
  <id_info>
    <org_study_id>Institut Jules Bordet</org_study_id>
    <nct_id>NCT01658956</nct_id>
  </id_info>
  <brief_title>Effectiveness of Reduced GCSF Dosing in Patients With a Low to Moderate Risk of Febrile Neutropenia</brief_title>
  <acronym>PAPALDO</acronym>
  <official_title>A Phase II Randomized Study to Verify the Papaldo's Hypothesis : the Effectiveness of a Reduced Dosing of G-CSF in Chemotherapy-treated Patients With a Low to Moderate Risk of Febrile Neutropenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jules Bordet Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jules Bordet Institute</source>
  <oversight_info>
    <authority>Belgium: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to confirm that a reduced dosage of GCSF is effective in preventing febrile
      neutropenia among patients with breast cancer, treated with chemotherapy and presenting with
      a low to moderate risk of developing febrile neutropenia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Occurrence of a febrile neutropenic episode defined as fever (&gt;=38.5°C once or &gt;=38°C twice within 12 hours interval) and neutropenia (ANC &lt; 0.5 IU)</measure>
    <time_frame>At the beginning of 2nd chemotherapy cycle, no more than 30 days after randomization</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Need for unplanned hospitalization</measure>
    <time_frame>At the beginning of second chemotherapy cycle, no more than 30 days after randomization</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Unplanned hospitalization is defined as the need to admit a patient outside of the schedule that was planned for chemotherapy administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complicated febrile neutropenic episode</measure>
    <time_frame>At the beginning of the second chemotherapy cycle, no more than 30 days after randomization</time_frame>
    <safety_issue>No</safety_issue>
    <description>A complicated febrile neutropenic episode is defined as a febrile neutropenic episode (see above) that does not resolve without the occurrence of serious medical complication as defined in Klasterky J et al; JCO 2000 : 3038-3051</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality any cause</measure>
    <time_frame>30 days from randomization</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">142</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Subcutaneous GCSF 5 µg/kg days 8 and 12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prophylactic administration of GCSF on days 8 and 12 following chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GCSF administration on days 8 and 12 after chemotherapy</intervention_name>
    <arm_group_label>Subcutaneous GCSF 5 µg/kg days 8 and 12</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Breast cancer Chemotherapy administration (new line) Chemotherapy type : FEC, EC, AC,
        docetaxel containing regimen Chemotherapy setting : adjuvant or neoadjuvant

        Exclusion Criteria:

        Eligibility to receive reimbursed GCSF
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aspasia Georgala, MD</last_name>
      <phone>3225413255</phone>
      <email>aspasia.georgala@bordet.be</email>
    </contact>
    <contact_backup>
      <last_name>Marianne Paesmans</last_name>
      <phone>3225413399</phone>
      <email>marianne.paesmans@bordet.be</email>
    </contact_backup>
    <investigator>
      <last_name>Aspasia Georgala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 13, 2014</lastchanged_date>
  <firstreceived_date>July 27, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GCSF</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Breast cancer</keyword>
  <keyword>Prophylaxis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
